Martini Jeffrey S
Chief Scientific Officer
Martini Jeffrey S has filed 1 SEC Form 4 filing (16 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.
On the most recent filing, Martini Jeffrey S is listed as Chief Scientific Officer at PALVELLA THERAPEUTICS, INC. Inside the rolling window, Martini Jeffrey S reported no open-market purchases and 2 open-market sales totaling $2.1M in PVLA. The largest disclosed transaction in the window is a sale of 6,250 PVLA shares on Nov 10, 2026, worth $1.0M.
Companies traded
Other insiders at PVLA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Martini Jeffrey S made?
Martini Jeffrey S has filed 1 SEC Form 4 filing (16 transaction rows) across 1 company since 2026.
Which companies does Martini Jeffrey S trade?
Martini Jeffrey S has filed SEC Form 4 disclosures for 1 company, including PVLA.
When was Martini Jeffrey S's most recent SEC Form 4 filing?
Martini Jeffrey S's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.
What is Martini Jeffrey S's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Martini Jeffrey S is listed as Chief Scientific Officer.
What is Martini Jeffrey S's total buy and sell value in the current window?
Inside the rolling retention window, Martini Jeffrey S bought $0 and sold $2.1M based on SEC Form 4 filings.
What was Martini Jeffrey S's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,250 PVLA shares on 2026-11-10, worth $1.0M, per SEC Form 4 filings.